We have developed a strategy of therapeutic vaccination against lymphoma that we interdigitate with conventional autologous hematopoietic cell transplantation (autoHCT). Autologous tumor cells are activated ex vivo with a TLR9 ligand (CpG oligonucleotide), irradiated, and then used as a vaccine to induce a T cell immune response in the patient against the tumor. The immune T cells are collected and then re-infused into the patient immediately after autoHCT. The goal is to allow the T cells to expand in the patient during the period of immunologic recovery and to mediate immune rejection of residual tumor. This strategy has a number of important features: -Simplicity: No tumor antigens need be identified in advance;instead the whole tumor cell is the vaccine. The activation step employs an """"""""off the shelf, chemically defined substance (CpG oligonucleotide) with a track record of safety and effectiveness as an immune stimulant in lymphoma. -Feasibility: We have now performed the entire treatment strategy under our IND without adverse effects. -Homeostatic T cell proliferation: We have shown in preclinical models that during the immediate post transplantation period adoptively transferred T cells expand and that T effector cells preferentially do so over T regulatory cells, resulting in powerful therapeutic effects. We have initiated a clinical trial for patients newly diagnosed with Mantle Cell Lymphoma and have accrued 35 patients during the first 3 years. Sixteen of these patients have completed the entire treatment program and nine of eleven evaluable patients have achieved the primary endpoint of CR with negative minimal residual disease (MRD) assays at one year. Since our original goals of feasibility and of inducing anti-tumor immune responses have been achieved we are now expanding the trial with a defined goal of freedom from MRD at one year of greater than or equal to 85% using a highly sensitive method of measurement, high-throughput sequencing.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Sen, Nandini; Arvin, Ann M (2016) Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells. J Virol 90:3284-7
Pierini, Antonio; Alvarez, Maite; Negrin, Robert S (2016) NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells Int 2016:9025835
Khodadoust, M S; Luo, B; Medeiros, B C et al. (2016) Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30:947-50
Xu, Lian; Hunter, Zachary R; Tsakmaklis, Nicholas et al. (2016) Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol 172:735-44
Pierini, Antonio; Strober, William; Moffett, Caitlin et al. (2016) TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood 128:866-71
Nakasone, Hideki; Sahaf, Bita; Tian, Lu et al. (2016) Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. Haematologica 101:e30-3
Pierini, Antonio; Colonna, Lucrezia; Alvarez, Maite et al. (2015) Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. J Immunol 195:347-55
Ohgami, Robert S; Ma, Lisa; Merker, Jason D et al. (2015) Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol 28:706-14
Nakasone, Hideki; Remberger, Mats; Tian, Lu et al. (2015) Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica 100:1477-85
Kelley, Todd W; Arber, Daniel A; Gibson, Christine et al. (2015) Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)). Arch Pathol Lab Med :

Showing the most recent 10 out of 292 publications